Enasidenib
Back to searchMolecule Structure
Scientific Name
Enasidenib
Description of the Drug
Enasidenib is an isocitrate dehydrogenase-2 inhibitor used to treat relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB13874
http://www.drugbank.ca/drugs/DB13874
Brand Name(s)
Not Available
Company Owner(s)
Celgene Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Isocitrate dehydrogenase [NADP], mitochondrial | SINGLE PROTEIN | INHIBITOR | CHEMBL3991501 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL15102202 | ||
| Human Metabolome Database | HMDB0251786 | ||
| DrugBank | DB13874 | ||
| PubChem | 89683805 | ||
| PDBe | 69Q | ||
| BindingDB | 50503251 | ||
| DrugCentral | 5251 | ||
| ChemicalBook | CB53044318 | ||
| Guide to Pharmacology | 8960 | ||
| rxnorm | IDHIFA | ENASIDENIB | ENASIDENIB MESYLATE |
| ChEBI | 145374 | ||
| ZINC | ZINC000222731806 |
